CYTOMX THERAPEUTICS INC. WKN: A14158 ISIN: US23284F1057 Kürzel: CTMX Forum: Aktien Thema: Hauptdiskussion

Soviel zum Thema entspanntes anlegen :-)

KE 75 Mio

https://ih.advfn.com/p.php?pid=nmona&article=84124991

Ziel Gap Close😁

Neue Options an MA.

Entspanntes Anlegen.

Unser schlafender Riese präsentiert sich: Stern IR Virtual Conference am 11. Januar 2021

Heute letzter Kauf. Kann losgehen ✌

FUTURE MILESTONES • CX-2009 Phase 2 HR+/HER2- Breast Cancer • CX-2009 + CX-072 Phase 2 TNBC • CX-2029 Phase 2 expansions • BMS-986249 randomized Phase 2 • CX-904 (EGFR-CD3) IND • Additional IND(s) from internal and partnered discovery programs

Keine Schulden, keine Warrants👍👍👍

Da ist laut Präsentation einiges los. Hammerkurs, zur Zeit.

Growing evidence Probody Platform can unlock clinical potential in previously undruggable targets and enable improved immune checkpoint inhibition Phase 1 data for CX-2029 (Anti-CD71) underpin recent $40 million AbbVie milestone and support Phase 2 expansion studies - CX-2029 global co-development alliance with AbbVie with 35% US commercial rights retained Phase 2 data for CX-2009 (Anti-CD166) support Breast Cancer Phase 2 Strategy CX-2009 remains wholly-owned by CytomX Continued progress with Probody Checkpoint Inhibitor programs • BMS-986249 (Anti-CTLA4) Phase 1 data support ongoing randomized Phase 2 expansion in melanoma • CX-072 (Anti-PD-L1) durable clinical benefit in multiple tumor types with favorable tolerability profile

Leader in field of “conditional activation” of therapeutic antibodies with broad platform and discovery engine • Initial clinical proof of concept established for platform • Pipeline advancing from Phase 1 to Phase 2 • Potential first-in-class programs against previously undruggable targets: Probody Drug Conjugates to CD166 (CX-2009) and CD71 (CX-2029) • Potential best-in-class programs against validated targets: CX-072 (anti-PD-L1), BMS-986249, BMS-986288 (anti-CTLA-4) • Major Partnerships (BMS, AbbVie, Amgen, Astellas) • Strong balance sheet; $248 million at end of Q1 2020; additional $130 million in milestone and upfront payments achieved in Q1 and received in Q2

Danke für den Hinweis 🤪🤪🤪

Nur wenn konkrete Ergebnisse kommen !

Wer noch nicht dabei ist, könnte den gestrigen Dip nutzen und einsteigen. Plattform wird nächstes Jahr an der Wallstreet ankommen.